RankingsPricing
  1. US-listed companies
  2. CAPRICOR THERAPEUTICS, INC.
  3. Financials
  4. Research & development

CAPRICOR THERAPEUTICS, INC.CAPR

Market cap
$1.2B
P/E ratio
SummaryFinancials
Period EndResearch & development (Million USD)YoY (%)
Dec 31, 202450+37.36%
Dec 31, 202336+66.97%
Dec 31, 202222+60.29%
Dec 31, 202114+60.81%
Dec 31, 20208+64.48%
Dec 31, 20195-57.39%
Dec 31, 201812+12.08%
Dec 31, 201711-32.89%
Dec 31, 201616+16.61%
Dec 31, 201514+76.66%
Dec 31, 20148-32.28%
Dec 31, 201311-62.93%
Dec 31, 201231+3.41%
Dec 31, 201130

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)